DSIP
Also known as: Delta Sleep-Inducing Peptide, Emideltide, Deltaran
What Is DSIP?
DSIP — Delta Sleep-Inducing Peptide — is a nonapeptide discovered in the mid-1970s by Marcel Monnier and Guido Schoenenberger at the University of Basel. They electrically stimulated the thalamus of rabbits to induce slow-wave (delta) sleep, collected cerebral venous blood, and isolated a peptide fraction that induced delta sleep when injected into recipient rabbits. The sequence was determined and synthesized in 1977–78.
The FDA refers to DSIP as Emideltide — the name it used when removing the peptide from Category 2 in April 2026. It’s marketed for sleep, stress reduction, and recovery, and sometimes for opioid-withdrawal mitigation.
What the Evidence Actually Shows
DSIP is a good illustration of how a peptide can be genuinely old and genuinely under-studied at the same time. Most of the literature dates from the 1970s to 1990s, much of it from the original discovering group. The human clinical data are sparse, small (single-digit to roughly 16 subjects), and mixed — some early double-blind crossover trials reported longer sleep, while at least one clinical study concluded DSIP was unlikely to be of major therapeutic benefit for chronic insomnia. Reviews describe the evidence on whether DSIP is truly involved in sleep regulation as conflicting.
A central scientific problem remains unresolved: no DSIP gene, precursor protein, or specific receptor has ever been identified. That absence undercuts strong mechanistic claims — it’s difficult to explain how a peptide produces a specific physiological effect when its target is unknown. Modern research is limited and mostly preclinical.
Because small human trials do exist (which is more than animal-only), but they are minimal, decades old, largely from one group, inconsistent, and never replicated in modern well-powered studies, we rate DSIP limited-human.
Legal and Regulatory Status
FDA: Removed from Category 2 on April 15, 2026 (listed by the FDA as “Emideltide”). Removal from the “do not compound” list is not authorization — DSIP is not yet on the 503A compoundable list, so licensed pharmacies still cannot lawfully compound it. PCAC reviews it on July 24, 2026, after which any 503A listing would require FDA rulemaking. Not FDA-approved for any indication.
WADA: Not explicitly named on the Prohibited List; as a non-approved substance it would fall under S0 (non-approved substances), prohibited in sport at all times.
Common Vendor Claims vs. Reality
| What vendors say | What the evidence shows |
|---|---|
| ”Clinically proven sleep aid” | Human trials are tiny, decades old, and mixed; results were not robustly replicated |
| ”Natural sleep regulator” | No DSIP gene, precursor, or receptor has ever been identified |
| ”Aids opioid withdrawal / recovery” | These marketing claims outrun the peer-reviewed evidence |
| ”Well-studied since the 1970s” | Studied early, then largely abandoned; little modern human data exists |
The Bottom Line
DSIP has a long history and a short evidence base. The sleep effects that made it famous in the 1970s were never robustly replicated, and half a century later it still has no identified receptor. Its April 2026 removal from Category 2 changed its regulatory status, not the underlying science — it remains unapproved and not lawfully compoundable pending the July 24, 2026 PCAC review.
Related: What Is the FDA Peptide Reclassification? | Early July 2026 Roundup